Zomedica Corp. (ZOM)
$
0.1
Key metrics
Financial statements
Free cash flow per share
-0.0200
Market cap
95.3 Million
Price to sales ratio
3.5675
Debt to equity
0.0102
Current ratio
10.8222
Income quality
0.3831
Average inventory
5.5 Million
ROE
-0.2816
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Zomedica Corp., a veterinary health company centered on addressing the unmet needs of clinical veterinarians, develops innovative products for companion animals. The company's operational efficiency is highlighted by its EBITDA ratio of -1.17. For the fiscal year 2024 Zomedica reported a gross profit of $17,318,000.00 underscoring its profitability from core operations. The company faced an income tax expense of -$1,331,000.00 reflecting its tax obligations, while also reporting depreciation and amortization expenses of $6,298,000.00 which indicate the wear and tear on its assets. With advancements in veterinary diagnostics, Zomedica has made significant strides through its TRUFORMA platform, providing point-of-care diagnostic products for dogs and cats. Moreover, the PulseVet service addresses various musculoskeletal issues in both horses and small animals. Collaborative agreements with Celsee, Inc. aim to develop and market liquid biopsy assays for cancer detection in companion animals, while a partnership with Seraph Biosciences, Inc. focuses on creating a novel pathogen detection system. Originally named Zomedica Pharmaceuticals Corp., the company rebranded to Zomedica Corp. in October 2020 and has its headquarters in Ann Arbor, Michigan, founded in 2015. In the stock market, Zomedica's shares are appealing to budget-conscious investors, priced affordably at $0.10. The stock's high average trading volume of 8,541,418.00 indicates strong liquidity, making it an attractive choice for potential investors. With a market capitalization of $95,349,137.00 Zomedica is classified as a small-cap player within the broader financial landscape. This positioning is significant, as Zomedica is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing meaningfully to the market's overall dynamic. Additionally, the company operates within the Healthcare sector, driving ongoing innovation and growth, which further enhances its potential for future developments in veterinary health care.
What is Zomedica Corp. (ZOM)'s stock forecast?
Analysts predict Zomedica Corp. stock to fluctuate between $0.02 (low) and $0.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Zomedica Corp.'s market capitalization?
As of 2025-03-04, Zomedica Corp.'s market cap is $95,349,137, based on 979,950,016 outstanding shares.
How does Zomedica Corp. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Zomedica Corp. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Zomedica Corp. (ZOM) stock?
To buy Zomedica Corp. (ZOM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ZOM. Place an order (Market, Limit, etc.).
What is the best time to invest in Zomedica Corp.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Zomedica Corp. perform in the last earnings report?
Revenue: $25,186,000 | EPS: -$0.04 | Growth: 102.30%.
Where can I find Zomedica Corp.'s investor relations reports?
Visit https://www.zomedica.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Zomedica Corp.?
You can explore historical data from here
What is the all-time high and low for Zomedica Corp. stock?
All-time high: $2.98 (2018-06-22) | All-time low: $0.06 (2020-11-03).
What are the key trends affecting Zomedica Corp. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
Engaging Sessions to Highlight Game-Changing Technologies, Expert Insights, and Growth Opportunities in Animal Health Featuring Zomedica Products ANN ARBOR, MI / ACCESS Newswire / May 19, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of a new monthly webinar series designed to highlight its innovative product portfolio, introduce key personnel, showcase manufacturing capabilities, and educate investors and strategic partners on the company's long-term growth strategy. This exclusive webinar series scheduled for the fourth Friday of every month beginning May 23rd, offers a front-row seat to Zomedica's game-changing technologies and strategic vision, providing veterinarians, investors, and industry leaders with an unparalleled opportunity to stay ahead of the curve in animal healthcare.
zacks.com
Zomedica Corp. (ZOMDF) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.01 per share a year ago.
accessnewswire.com
ANN ARBOR, MI / ACCESS Newswire / May 15, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2025. "We are pleased with our performance in the first quarter as we posted record year over year revenue for the 17th straight quarter," said Larry Heaton, President and Chief Executive Officer of Zomedica.
accessnewswire.com
ANN ARBOR, MI / ACCESS Newswire / May 9, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, May 15, 2025, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its first quarter ended March 31, 2025.
seekingalpha.com
Zomedica Corp. (OTC:ZOMDF) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Mike Vallie – ICR Larry Heaton – Chief Executive Officer Scott Jordan – Executive Vice President and Chief Financial Officer Mike Zuehlke – Vice President of Finance and Corporate Controller Conference Call Participants Robert LeBoyer – Noble Capital Markets Robert Sassoon – Water Tower Research Andrew Rem – Odinson Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Zomedica Fourth Quarter 2024 Financial Results Conference Call. At this time all lines are in listen-only mode.
businesswire.com
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common shares of Zomedica Corp. (the “Company”) — ticker symbol ZOM — from NYSE American. Trading in the Company's common shares will be suspended immediately. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to.
accessnewswire.com
ANN ARBOR, MI / ACCESS Newswire / February 26, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, March 13, 2025, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its fourth quarter and full year ended December 31, 2024.
See all news
